Meeting
2023 ASCO Quality Care Symposium
Comparison of molecular testing rates and biomarker positivity by histology among patients (pts) with stage IV non-small cell lung cancer (NSCLC): A quality initiative by Integra Connect PrecisionQ.
Authors
Simon Blanc
Integra Connect PrecisionQ, West Palm Beach, FL
Simon Blanc, Mike Gart, Anupama Vasudevan, Justin Scott, Fred J. Kudrik
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Use of IT/Analytics to Improve Quality
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 582)
DOI
10.1200/OP.2023.19.11_suppl.582
Abstract #
582
Poster Bd #
N5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox
Poster
2023 ASCO Annual Meeting
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).
First Author: Samuel Rosner
Poster
2023 ASCO Annual Meeting
Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.
First Author: Benjamin Herzberg
Poster
2023 ASCO Annual Meeting
A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.
First Author: Benjamin J. Solomon